Resultados da pesquisa - Kenshi Suzuki

Refinar resultados
  1. 1
    Formation and Reversion of Streptomycete Protoplasts: Cultural Condition and Morphological Study

    Formation and Reversion of Streptomycete Protoplasts: Cultural Condition and Morphological Study Por Masanori Okanishi, Kenshi Suzuki, Hitoshi Umezawa

    Publicado em 1974
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress

    Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress Por Kenshi Suzuki, Ariungerel Gerelchuluun, Zhengshan Hong, Lue Sun, Junko Zenkoh, Takashi Moritake, Koji Tsuboi

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

    Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours Por Andrew J. Nicol, Hirotake Tokuyama, Stephen R. Mattarollo, Tomomi Hagi, Kenshi Suzuki, Kiyoshi Yokokawa, Mie Nieda

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Human invariant Vα24<sup>+</sup> natural killer T cells activated by α‐galactosylceramide (KRN7000) have cytotoxic anti‐tumour activity through mechanisms distinct from T cells and natural killer cells

    Human invariant Vα24<sup>+</sup> natural killer T cells activated by α‐galactosylceramide (KRN7000) have cytotoxic anti‐tumour activity through mechanisms distinct from T cells and... Por Andrew J. Nicol, Mie Nieda, Yasuhiko Koezuka, S Porcelli, Kenshi Suzuki, Kenji Tadokoro, Simon Durrant, Takeo Juji

    Publicado em 2000
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

    Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders Por Seiichiro Yoshizawa, Junko H. Ohyashiki, Michiyo Ohyashiki, Tomohiro Umezu, Kenshi Suzuki, Atsushi Inagaki, Shinsuke Iida, Kazuma Ohyashiki

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

    Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma Por Yu Abe, Masato Muto, Mie Nieda, Yasunori Nakagawa, Andrew J. Nicol, Touru Kaneko, Shigenori Goto, Kiyoshi Yokokawa, Kenshi Suzuki

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

    LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY Por Edvan de Queiroz Crusoé, Thierry Façon, Philippe Moreau, Ivan Špıčka, Kenshi Suzuki, Kwee Yong, Joseph Mıkhael, Takanori Fukao, Nicole M. Armstrong, T. Martin

    Publicado em 2023
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    The Major DNA Repair Pathway after Both Proton and Carbon-Ion Radiation is NHEJ, but the HR Pathway is More Relevant in Carbon Ions

    The Major DNA Repair Pathway after Both Proton and Carbon-Ion Radiation is NHEJ, but the HR Pathway is More Relevant in Carbon Ions Por Ariungerel Gerelchuluun, Eri Manabe, Takaaki Ishikawa, Lue Sun, Kazuya ITOH, Takeji Sakae, Kenshi Suzuki, Ryoichi Hirayama, Aroumougame Asaithamby, David J. Chen, Koji Tsuboi

    Publicado em 2015
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

    Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA Por Tom Martin, Paul G. Richardson, Thierry Façon, Philippe Moreau, Aurore Perrot, Ivan Špıčka, Kamlesh Bisht, Marlène Inchauspé, France Casca, Sandrine Macé, Helgi van de Velde, Kenshi Suzuki

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    POSTER: MM-248 Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+ Status: Updated Results from the Phase 3 IKEMA Study

    POSTER: MM-248 Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+ Status: Updated Results from the Ph... Por Thierry Façon, Philippe Moreau, Ivan Špıčka, Kenshi Suzuki, Kwee Yong, Joseph Mıkhael, Taro Fukao, Kamlesh Bisht, Nicole D. Armstrong, Sandrine Macé, Marie‐Laure Risse, Thomas G. Martin

    Publicado em 2023
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

    Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation Por Shuji Ozaki, Takeshi Harada, Takayuki Saitoh, Chihiro Shimazaki, Mitsuhiro Itagaki, Hideki Asaoku, Yoshiaki Kuroda, Takaaki Chou, Yumiko Yoshiki, Kenshi Suzuki, Hirokazu Murakami, Kunihiko Hayashi, Roberto Mina, Antonio Palumbo, Kazuyuki Shimizu

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

    Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL... Por Angela Dispenzieri, Eftathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, Kihyun Kım, Vaishali Sanchorawala, Heather Landau, Fiona Kwok, Kenshi Suzuki, Raymond L. Comenzo, Deborah Berg, Guohui Liu, Douglas V. Faller, Giampaolo Merlini

    Publicado em 2019
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia

    A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia Por Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi, Koji Izutsu

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia

    Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia Por Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

    Publicado em 2022
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis

    A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis Por Angela Dispenzieri, Efstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, Kihyun Kım, Vaishali Sanchorawala, Heather Landau, Fiona Kwok, Kenshi Suzuki, Raymond L. Comenzo, Deborah Berg, Guohui Liu, Arun Kumar, Douglas V. Faller, Giampaolo Merlini

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation

    Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation Por Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michèle Cavo, Philippe Moreau, Meletios Α. Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie‐Laure Risse, Joseph Mıkhael

    Publicado em 2022
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

    The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma Por Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Façon, Ivan Špıčka, Albert Oriol, Kenshi Suzuki, Edvan de Queiroz Crusoé, Ajai Chari, Nicole M. Armstrong, Christina Tekle, Marie‐Laure Risse, Thomas G. Martin, Philippe Moreau

    Publicado em 2023
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

    Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma Por Shuji Ozaki, Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, Mitsuhiro Itagaki, Hideki Asaoku, Kenshi Suzuki, Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Jun Konishi, Kazutaka Sunami, Naoki Takezako, Shotaro Hagiwara, Y Kuroda, Takaaki Chou, E Nagura, Kazuyuki Shimizu

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  19. 19
    Severe loss of invariant NKT cells exhibiting anti–HTLV-1 activity in patients with HTLV-1–associated disorders

    Severe loss of invariant NKT cells exhibiting anti–HTLV-1 activity in patients with HTLV-1–associated disorders Por Kazuko Azakami, Tomoo Sato, Natsumi Araya, Atae Utsunomiya, Ryuji Kubota, Kenshi Suzuki, Daisuke Hasegawa, Toshihiko Izumi, Hidetoshi Fujita, Satoko Aratani, Ryoji Fujii, Naoko Yagishita, Hajime Kamijuku, Takuro Kanekura, Ken‐ichiro Seino, Kusuki Nishioka, Toshihiro Nakajima, Yoshihisa Yamano

    Publicado em 2009
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

    Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial Por Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: